Strides Pharma Science announced that while the company conducts the relevant tests mandated by the USFDA, it has suspended
sales of ranitidine tablets in the US market until such time it has clarity of next steps as would
be indicated by the USFDA.
The Company predominantly sells Ranitidine tablets in the US markets, and its front end sales globally for the product were ~US$ 9 million in H1FY20.
In spite of this temporary suspension of the ranitidine supplies, the Company retains its FY20 growth outlook for the US markets.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
